Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2537 - A phase 1b study evaluating the safety and pharmacokinetics (PK) of regorafenib (REG) in combination with cetuximab (CTX) in patients with advanced solid tumors

Date

11 Sep 2017

Session

Poster display session

Presenters

Colin Weekes

Citation

Annals of Oncology (2017) 28 (suppl_5): v122-v141. 10.1093/annonc/mdx367

Authors

C. Weekes1, A.C. Lockhart2, H. Lenz3, J.J. Lee4, A. Cleton5, F. Huang6, I. Sturm7

Author affiliations

  • 1 Division Of Hematology/oncology, Massachusetts General Hospital, 02114 - Boston/US
  • 2 Department Of Medicine, University of Miami, 33146 - Coral Gables/US
  • 3 Division Of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, 90089-9173 - Los Angeles/US
  • 4 Division Of Hematology-oncology, Department Of Medicine, University of Pittsburgh School of Medicine, 15261 - Pittsburgh/US
  • 5 Clinical Pharmacology Oncology, Bayer AG, 13353 - Berlin/DE
  • 6 Clinical Pharmacology Oncology, Bayer HealthCare Pharmaceuticals, 07981 - Whippany/US
  • 7 Translational Medicine Oncology, Bayer AG, 13353 - Berlin/DE
More

Resources

Abstract 2537

Background

Combining REG with CTX may overcome intrinsic and acquired resistance in EGFR-sensitive and -resistant tumors. We evaluated the safety, PK, maximum tolerated dose (MTD), and preliminary efficacy of REG plus standard dose of CTX (initial 400 mg/m2 intravenously followed by 250 mg/m2 weekly) in a phase 1b study. Final results from the intermittent REG dosing arm (3 weeks on/1 week off) are reported, with final results from the terminated continuous REG dosing arm (n = 11) previously presented (Weekes et al. AACR 2016, abstract CT148).

Methods

This was an open-label, dose-escalation (3 + 3 design) study in patients with locally advanced or metastatic solid tumors who progressed after standard therapy. The starting dose of REG was 120 mg once daily (QD) in a 28-day cycle (3 weeks on/1 week off) plus CTX. If tolerable, REG was escalated to 160 mg QD. If not tolerable, the REG dose was reduced to 80 mg QD. Dose-limiting toxicities (DLTs) were evaluated in Cycle 1. Adverse events (AEs) were graded according to NCI-CTCAE v4.03. Antitumor activity was assessed using RECIST v1.1.

Results

As of January 31, 2017, 31 patients received REG in an intermittent schedule plus CTX: 8 patients received REG 120 mg and 23 received REG 160 mg. One DLT of grade 3 hand–foot skin reaction was reported in 6 evaluable patients at the 120 mg dose level. No DLT was confirmed at the 160 mg dose level. The MTD was declared at the standard dose of REG 160 mg QD (3 weeks on/1 week off) plus the standard dose of CTX. The most common AEs, regardless of relationship to study drug, were hypophosphatemia (42%), fatigue (39%), and nausea (39%). The most common grade ≥3 REG-related AEs were hypophosphatemia (23%) and fatigue (10%). REG AUC(0–tlast) was 29.1 mg·h/L at 160 mg and 17.4 mg·h/L at 120 mg. CTX had no effect on the PK of REG. One patient (120 mg REG) had a partial response; 6 (160 mg REG; 29%) and 2 (120 mg REG; 25%) patients had stable disease.

Conclusions

REG at 160 mg QD (3 weeks on/1 week off) plus standard dose of CTX was tolerated with no unexpected toxicities. Observed AEs were in line with known REG and CTX safety profiles.

Clinical trial identification

NCT01973868

Legal entity responsible for the study

Bayer

Funding

Bayer

Disclosure

C. Weekes: Advisory Board: Celgene, Merrimack, Bayer. A.C. Lockhart: Corporate Sponsored Research: Amgen, Bayer, Daiichi Sankyo, EMD Serono, Genentech/Roche, Eli Lilly, Millennium/Takeda, Novartis, Sanofi, Teva, Zenyaku Kogyo. H-J. Lenz: Research/Education Grant, Honoraria, Advisory Board and Consulting: Bayer, EMD. J.J. Lee: Research/Education Grant: Merck Advisory Board: Genentech/Roche. A. Cleton: Employment: Bayer. Stock Ownership: Bayer, Pfizer. F. Huang, I. Sturm: Employment and Stock Ownership: Bayer.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.